In a study using ACCEPT, various populations of EpCAM-enriched circulating cells in non-small cell lung cancer (NSCLC) patient blood and healthy blood with spiked cancer cells were analyzed by adding a stain for a granulocyte marker (such as CD16), allowing them to decrease the number of unidentified nucleated cells in the blood [44]. Here, EPCAM is linked to non-small cell lung carcinoma.